Loading…
Hosted by Unknown Host · 🇺🇸 US · EN · 300 episodes
Established thought leaders with verified media credentials.
CANCER BUZZ features fresh perspectives on hot topics in oncology care delivery. CANCER BUZZ is where stakeholders from the front lines of care to the C-suite, from research to the registry, from chairside to benchside, talk about top-of-mind questions and real-world impact.
Unknown Host hosts CANCER BUZZ, a science show with 300 episodes published.
Revenue cycle operations teams are responsible for maintaining reimbursement integrity and regulatory compliance across a rapidly expanding oncology service line. Increasing payer scrutiny—particularly for high-cost onco
Bispecific antibodies (BsAbs) continue to garner the interest of both academic and community cancer centers due to their rapid growth in FDA approvals and increasing use in hematologic malignancies and solid tumors. Howe
As bispecific antibodies (BsAbs) become more integrated into oncology care, much of the focus has been placed on clinical protocols and operational readiness. However, less attention has been paid to the patient and care
Jon Treffert was diagnosed with locally advanced muscle-invasive bladder cancer in September 2023. After 2 years of treatment, including surgical resection and 6 months with an antibody-drug conjugate (ADC), he had no ev
In this episode of Oncology Unscripted, hosts Mark Liu and Deirdre Saulet speak with Arif Kamal, MD, Chief Patient Officer at the American Cancer Society (ACS). Dr. Kamal discusses his recent appointment to this inaugura
Oncolytic viruses are a novel and effective way to treat cancers by infecting and destroying cancer cells, but clinical delivery necessitates creative strategies to account for the required safety protocols, deep-freeze
In 2025, the FDA approved the antibody-drug conjugate (ADC) enfortumab vedotin combined with pembrolizumab for patients with cisplatin-ineligible muscle-invasive bladder cancer, unlocking a new perioperative treatment op
At the University of California, San Francisco (UCSF), the team treating patients with bladder cancer and other genitourinary malignancies utilizes a multidisciplinary team approach to ensure care is coordinated, persona
Myelodysplastic syndromes (MDS), a rare category of bone marrow disorders that may develop into acute myeloid leukemia, are categorized into risk groups ranging from very low to very high risk. However, this language can
From the moment a woman learns that she has breast cancer, her life is forever changed—from the treatment challenges of chemotherapy, radiation, and surgery to the personal and emotional challenges of a change in identit
Radiation therapy is a powerful and non-invasive tool in the management of small cell lung cancer (SCLC), but radiation oncologists are not always fully integrated into the care team. In this episode, CANCER BUZZ speaks
Bispecific antibodies (BsAbs) are an emerging and fast-developing area of immunotherapy, particularly in the treatment of hematologic malignancies. However, access to this therapy remains limited, particularly for Vetera
Toxicities related to antibody-drug conjugates (ADCs) can significantly impact quality of life for patients with locally advanced or metastatic bladder cancer, but data-driven programs can help multidisciplinary teams ma
The ACCC Global eXchange series is committed to highlighting cross-regional collaborations that advance cancer care delivery and workforce development nationwide. In this episode of CANCER BUZZ, Dr. Michael Cavnar discus
At the inaugural ACCC Leadership Summit, C-suite executives and senior-level decision makers in oncology convened for strategic dialogue, panel discussions, and peer-to-peer exchange focused on the most pressing issues i
At the inaugural ACCC Leadership Summit, C-suite executives and senior-level decision makers in oncology convened for strategic dialogue, panel discussions, and peer-to-peer exchange focused on the most pressing issues i
At the inaugural ACCC Leadership Summit, C-suite executives and senior-level decision makers in oncology convened for strategic dialogue, engaging panel discussions, and peer-to-peer exchange focused on the most pressing
At the inaugural ACCC Leadership Summit, C-suite executives and senior-level decision makers in oncology convened for strategic dialogue, engaging panel discussions, and peer-to-peer exchange focused on the most pressing
Indications for the use of bispecific antibodies (BsAbs) are rapidly increasing in oncology. While many cancer centers are keeping an eye on this developing field, curiosity must be transformed into proactive planning to
For 52 years, ACCC has brought together thousands of health care professionals from across the nation representing all disciplines in oncology. Today, with over 46,000 members, ACCC's mission remains the same: to provide
Ashley Johnson
chief innovation officer · Ashley’s Business Solutions
1 appearance on this show
Michelle Rozen
behavioral scientist
1 appearance on this show
Kathryn Kennedy
Vanderbilt-Ingram Cancer Center
1 appearance on this show
Arif Kamal
American Cancer Society
1 appearance on this show
Manojkumar Bupathi
Rocky Mountain Cancer Centers
1 appearance on this show
Iva Colón
UCSF Health Genitourinary Medical Oncology
1 appearance on this show
Terence Friedlander
UCSF Helen Diller Family Comprehensive Cancer Center
1 appearance on this show
Cindy Y. Jiang
MD Anderson Cancer Center
1 appearance on this show
Michael Cavnar
UK HealthCare
1 appearance on this show
Misha Kaur
Cureety
1 appearance on this show
Jay Seemann
BeOne Medicines
1 appearance on this show
Michele LeSueur
Johnson & Johnson
1 appearance on this show
Detected from recent episode content. Sponsor presence is a real signal of listener purchasing power and show monetisation.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
CANCER BUZZ has a verified contact on file. Create a free PitchCentric account to access it and generate a personalised pitch in seconds. Research at least 3 recent episodes first and lead with a specific angle that serves their science audience.
CANCER BUZZ is hosted by Unknown Host. The show is categorised under Science and has published 300 episodes.
CANCER BUZZ has published 300 episodes.
CANCER BUZZ regularly covers Science. It sits in the Science category.
CANCER BUZZ is accessible for guests with genuine science expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
CANCER BUZZ hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of CANCER BUZZ average 11 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates CANCER BUZZ's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched 2 days ago.